Global Neurodegenerative Diseases Therapeutics Market 2022-2026

Description

List of Tables

Technavio has been monitoring the neurodegenerative diseases therapeutics market and it is poised to grow by $ 19.74 bn during 2022-2026, accelerating at a CAGR of 7.98% during the forecast period. Our report on the neurodegenerative diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a strong drug development pipeline, high research funding on neurodegenerative diseases, and the availability of highly sensitive diagnostic modalities.

The neurodegenerative diseases therapeutics market analysis includes indication segment and geographic landscape.

Technavio's neurodegenerative diseases therapeutics market is segmented as below:

By indication

Multiple sclerosis
Alzheimers disease
Parkinsons disease
Huntingtons disease
Others

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increase in the aging population as one of the prime reasons driving the neurodegenerative diseases therapeutics market growth during the next few years. Also, an improved understanding of the genetic basis and molecular pathology of neurodegenerative diseases and a high economic burden will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the neurodegenerative diseases therapeutics market covers the following areas:

Neurodegenerative diseases therapeutics market sizing
Neurodegenerative diseases therapeutics market forecast
Neurodegenerative diseases therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurodegenerative diseases therapeutics market vendors that include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., F. Hoffmann La Roche Ltd., H Lundbeck AS, Mitsubishi Chemical Holdings Corp., Novartis AG, Sanofi, and Teva Pharmaceutical Industries Ltd. Also, the neurodegenerative diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR73294

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Indication

5.1 Market segments
Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)
5.2 Comparison by Indication
Exhibit 26: Chart on Comparison by Indication
Exhibit 27: Data Table on Comparison by Indication
5.3 Multiple sclerosis - Market size and forecast 2021-2026
Exhibit 28: Chart on Multiple sclerosis - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Multiple sclerosis - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Multiple sclerosis - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Multiple sclerosis - Year-over-year growth 2021-2026 (%)
5.4 Alzheimers disease - Market size and forecast 2021-2026
Exhibit 32: Chart on Alzheimers disease - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Alzheimers disease - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Alzheimers disease - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Alzheimers disease - Year-over-year growth 2021-2026 (%)
5.5 Parkinsons disease - Market size and forecast 2021-2026
Exhibit 36: Chart on Parkinsons disease - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Parkinsons disease - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Parkinsons disease - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Parkinsons disease - Year-over-year growth 2021-2026 (%)
5.6 Huntingtons disease - Market size and forecast 2021-2026
Exhibit 40: Chart on Huntingtons disease - Market size and forecast 2021-2026 ($ million)
Exhibit 41: Data Table on Huntingtons disease - Market size and forecast 2021-2026 ($ million)
Exhibit 42: Chart on Huntingtons disease - Year-over-year growth 2021-2026 (%)
Exhibit 43: Data Table on Huntingtons disease - Year-over-year growth 2021-2026 (%)
5.7 Others - Market size and forecast 2021-2026
Exhibit 44: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 45: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 46: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibit 47: Data Table on Others - Year-over-year growth 2021-2026 (%)
5.8 Market opportunity by Indication
Exhibit 48: Market opportunity by Indication ($ million)

6 Customer Landscape

6.1 Customer landscape overview
Exhibit 49: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
Exhibit 50: Chart on Market share by geography 2021-2026 (%)
Exhibit 51: Data Table on Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 52: Chart on Geographic comparison
Exhibit 53: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 54: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 62: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 66: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 70: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Canada - Market size and forecast 2021-2026
Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.9 UK - Market size and forecast 2021-2026
Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.10 Germany - Market size and forecast 2021-2026
Exhibit 82: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 83: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 84: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 85: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.11 Japan - Market size and forecast 2021-2026
Exhibit 86: Chart on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 87: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 88: Chart on Japan - Year-over-year growth 2021-2026 (%)
Exhibit 89: Data Table on Japan - Year-over-year growth 2021-2026 (%)
7.12 China - Market size and forecast 2021-2026
Exhibit 90: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 91: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 92: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 93: Data Table on China - Year-over-year growth 2021-2026 (%)
7.13 Market opportunity by geography
Exhibit 94: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 95: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends

9 Vendor Landscape

9.1 Overview
9.2 Vendor landscape
Exhibit 96: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 97: Overview on factors of disruption
9.4 Industry risks
Exhibit 98: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
Exhibit 99: Vendors covered
10.2 Market positioning of vendors
Exhibit 100: Matrix on vendor position and classification
10.3 AB Science SA
Exhibit 101: AB Science SA - Overview
Exhibit 102: AB Science SA - Product / Service
Exhibit 103: AB Science SA - Key offerings
10.4 AbbVie Inc.
Exhibit 104: AbbVie Inc. - Overview
Exhibit 105: AbbVie Inc. - Product / Service
Exhibit 106: AbbVie Inc. - Key offerings
10.5 Acadia Pharmaceuticals Inc.
Exhibit 107: Acadia Pharmaceuticals Inc. - Overview
Exhibit 108: Acadia Pharmaceuticals Inc. - Product / Service
Exhibit 109: Acadia Pharmaceuticals Inc. - Key offerings
10.6 Biogen Inc.
Exhibit 110: Biogen Inc. - Overview
Exhibit 111: Biogen Inc. - Product / Service
Exhibit 112: Biogen Inc. - Key offerings
10.7 F. Hoffmann La Roche Ltd.
Exhibit 113: F. Hoffmann La Roche Ltd. - Overview
Exhibit 114: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 115: F. Hoffmann La Roche Ltd. - Key news
Exhibit 116: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 117: F. Hoffmann La Roche Ltd. - Segment focus
10.8 H Lundbeck AS
Exhibit 118: H Lundbeck AS - Overview
Exhibit 119: H Lundbeck AS - Product / Service
Exhibit 120: H Lundbeck AS - Key offerings
10.9 Mitsubishi Chemical Holdings Corp.
Exhibit 121: Mitsubishi Chemical Holdings Corp. - Overview
Exhibit 122: Mitsubishi Chemical Holdings Corp. - Business segments
Exhibit 123: Mitsubishi Chemical Holdings Corp. - Key offerings
Exhibit 124: Mitsubishi Chemical Holdings Corp. - Segment focus
10.10 Novartis AG
Exhibit 125: Novartis AG - Overview
Exhibit 126: Novartis AG - Business segments
Exhibit 127: Novartis AG - Key offerings
Exhibit 128: Novartis AG - Segment focus
10.11 Sanofi
Exhibit 129: Sanofi - Overview
Exhibit 130: Sanofi - Business segments
Exhibit 131: Sanofi - Key news
Exhibit 132: Sanofi - Key offerings
Exhibit 133: Sanofi - Segment focus
10.12 Teva Pharmaceutical Industries Ltd.
Exhibit 134: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 135: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 136: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 137: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 138: Teva Pharmaceutical Industries Ltd. - Segment focus

11 Appendix

11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 139: Inclusions checklist
Exhibit 140: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 141: Currency conversion rates for US$
11.4 Research methodology
Exhibit 142: Research methodology
Exhibit 143: Validation techniques employed for market sizing
Exhibit 144: Information sources
11.5 List of abbreviations
Exhibit 145: List of abbreviations